Sophia Genetics’ SOPHiA DDM used by Acutis Diagnostics

SOPHiA GENETICS announced that Acutis Diagnostics will use SOPHiA DDM to develop a new genomic assay. This new next-generation sequencing, NGS, test will build on Acutis Diagnostics’ track record of approved lab-developed tests that support clinical trials, cancer research and treatment. "The use of SOPHiA DDM will help us quickly launch this new assay to aid clinical researchers in speeding up the process for launching select clinical oncology trials and ensuring the most appropriate patients are enrolled," said Dr. Abdel Halim, Chief Scientific Officer and Executive Vice President, Acutis Diagnostics. "Additionally, the test is to provide researchers with a robust set of data and insights to support clinical decision-making and future research."